25 results on '"Tsamandouras, Nikolaos"'
Search Results
2. Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
3. Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies.
4. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
5. Development and applications of physiologically-based pharmacokinetic models for population data analyses
6. Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis
7. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF‐06817024 in Healthy Participants, Participants With Chronic Rhinosinusitis With Nasal Polyps, and Participants With Atopic Dermatitis: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
8. Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
9. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
10. Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies
11. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data
12. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population
13. Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations
14. Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
15. Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction
16. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
17. Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics
18. Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
19. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data
20. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
21. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data
22. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach
23. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.
24. Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System
25. Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.